Close Menu

NEW YORK (GenomeWeb) – Invitae said today that it expects to report revenues of $59 million in 2017, which represents more than double year-over-year growth and is within its projected guidance.

In reporting preliminary financial results this week, Invitae estimated a 136 percent growth in 2017 revenues compared to $25 million in 2016. The company had issued year-end revenue guidance of between $55 million and $65 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.

Dec
03
Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.